FREMSLIFE SRL

FremsLife SRL produces two primary types of devices: diagnostic peripheral nerve electrical stimulation systems and single-use transcutaneous electrical stimulation electrodes. The nerve stimulation systems are designed to evaluate nerve function by delivering controlled electrical impulses, while the electrodes are intended for temporary skin application in therapeutic or diagnostic procedures.

FremsLife SRL is based in the United States. The company’s location is relevant for understanding its regulatory scope and compliance framework, particularly when navigating U.S. device authorisation processes.

FremsLife SRL’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry helps track and identify medical devices under U.S. regulatory oversight, ensuring traceability and compliance with classification requirements.

FremsLife SRL’s devices fall under Class II classification, which applies to devices posing moderate risk. This classification requires manufacturers to demonstrate compliance with specific regulatory controls, such as performance standards or post-market surveillance, to ensure safety and effectiveness before authorisation.